- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06174714
Effectiveness of Indo-SURFT in Reducing Addictive Substance Use in Women With Substance Use Disorders (Indo-SURFT)
July 10, 2024 updated by: Kristiana Siste, Indonesia University
Effectiveness of Indo-SURFT in Reducing Addictive Substance Use in Women With Substance Use Disorders: a Pilot Study
Relapse in women was associated with depression, interpersonal stress, and relationship conflict with others when compared with men.
The differences in gender profiles with substance use disorders (SUD) leads to the need for management strategies that are sensitive to each gender.
This is a challenge to build a new module that can be applied continuously by collaborating CBT and several other psychosocial interventions, such as motivational enhancement therapy.
The investigators compiled Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT).
By implementing this module, it is hoped that it can provide short and long term effects and reduce the relapse rate in women with SUD.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- women aged 18-59 years old
- diagnosed with substance use disorders based on DSM-V or ICD-10
Exclusion Criteria:
- subjects with severe mental disorder or intellectual disability
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: MI and Indo-SURFT
once a week motivational interviewing/motivational enhancement therapy (MI) for 4 weeks, followed by once a week CBT using Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT) for 8 weeks.
|
4 weeks of motivational interviewing/motivational enhancement therapy (MI) followed by 8 weeks cognitive behavioral therapy (CBT) using Indo-SURFT module.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Abstinence from Substance Use
Time Frame: post-intervention (week 13)
|
Timeline Follow Back (TLFB): to assess daily use of addictive substances by writing yes/no for 28 days.
This data will be collected weekly retrospectively to reduce the risk of recall bias.
|
post-intervention (week 13)
|
|
Decrease in Addiction Severity
Time Frame: pre-intervention (week 0), and post-intervention (week 13)
|
Addiction Severity Index (ASI), Indonesia version, measuring several domains: 1) Medical health (n= 11), 2) Employment/ support status (n= 24), 3 & 4) Drug/ alcohol use (n= 35), 5) Illegal activity/ legal status (n= 32), 6) Family/ social relationships (n= 38) and 7) Psychiatric health (n= 23).
Lesser score indicates better outcome.
|
pre-intervention (week 0), and post-intervention (week 13)
|
|
Improvement in Motivation to Change
Time Frame: pre-intervention (week 0), and post-intervention (week 13)
|
University of Rhode Island Change Assessment (URICA), measuring motivation to change with 4 domains: 1) pre-contemplation, 2) contemplation, 3) action, and 4) maintenance.
A higher score indicates a better outcome.
|
pre-intervention (week 0), and post-intervention (week 13)
|
|
Improvement in Substance Craving
Time Frame: pre-intervention (week 0), and post-intervention (week 13)
|
Visual Analog Scale (VAS), measuring substance craving severity.
Range 0 (no craving) - 100 (severe craving).
A lower score indicates a better outcome.
|
pre-intervention (week 0), and post-intervention (week 13)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improvement in Psychological Distress
Time Frame: pre-intervention (week 0), and post-intervention (week 13)
|
Self-Report Questionnaire-20 (SRQ-20), measuring non-specific psychological distress.
Score range 0-20; Scores >10 classified as mental distress.
A lower score indicates a better outcome.
|
pre-intervention (week 0), and post-intervention (week 13)
|
|
Improvement in Social Performance
Time Frame: pre-intervention (week 0), and post-intervention (week 13)
|
Personal and Social Performance (PSP), measuring social function.
A lower score indicates a better outcome.
|
pre-intervention (week 0), and post-intervention (week 13)
|
|
Improvement in Quality of Life
Time Frame: pre-intervention (week 0), and post-intervention (week 13)
|
World Health Organization Quality of Life (WHOQOL), measuring individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
A higher score indicates a better outcome.
|
pre-intervention (week 0), and post-intervention (week 13)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2024
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
March 1, 2025
Study Registration Dates
First Submitted
December 6, 2023
First Submitted That Met QC Criteria
December 13, 2023
First Posted (Actual)
December 18, 2023
Study Record Updates
Last Update Posted (Actual)
July 11, 2024
Last Update Submitted That Met QC Criteria
July 10, 2024
Last Verified
July 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KET-735-2023
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use Disorders
-
University of ArkansasNational Center for Advancing Translational Sciences (NCATS)RecruitingParenting | Substance Use Treatment | Perinatal Substance UseUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Substance Use Disorders | Cannabis Use | Alcohol Use, UnspecifiedUnited States
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Use Disorder | Substance Use Disorder (SUD)United States
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)Active, not recruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Indiana UniversityNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use Disorders | Nicotine Use DisorderUnited States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Spark Biomedical, Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA); Baylor College... and other collaboratorsRecruitingSubstance Use Disorders | Alcohol Use Disorder | Alcohol Abuse | Substance Use Disorders Alcohol Use Withdrawal StateUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Substance Use DisordersUnited States
Clinical Trials on Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT)
-
The University of Texas Health Science Center,...CompletedPosttraumatic Stress Disorder | Substance DependenceUnited States
-
University of California, San DiegoCompletedPTSD | Substance Use DisordersUnited States
-
VA Office of Research and DevelopmentUniversity of California, Los AngelesNot yet recruitingHomelessness | Substance Use Disorder (SUD)United States
-
Universidad de ZaragozaMinisterio de Sanidad, Servicios Sociales e IgualdadRecruitingImplementation ScienceSpain
-
Brown UniversityBoston University; Rhode Island Hospital; National Institute of General Medical... and other collaboratorsCompletedMedication Adherence | Opioid-use Disorder | Health Care UtilizationUnited States
-
Iowa City Veterans Affairs Medical CenterUS Department of Veterans AffairsCompleted
-
Mark Vander WegVA Office of Research and DevelopmentUnknownTobacco Use | Nicotine DependenceUnited States
-
Mark Vander WegIowa City VA Health Care SystemUnknownNicotine Dependence | Smokeless TobaccoUnited States
-
Mayo ClinicRecruitingFallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Primary Peritoneal Clear Cell Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Advanced Fallopian Tube Carcinoma | Advanced... and other conditionsUnited States